I nterleukin-18 is a pleiotropic cytokine initially discovered as an IFN-␥ inducing factor derived from liver cells (1, 2). Other biological activities of IL-18 include its ability to induce the production of inflammatory mediators, to enhance the cytotoxic activity of NK cells and T cells, and to augment the differentiation and activation of Th1 cells (1, 3-7). IL-12 and IL-18 single and double-knockout mice suggest that IL-18 is functionally closely related to IL-12 and plays a fundamental role in Th1 cell responses (8). However, IL-18 is predicted to fold as a ␤-rich trefoil, which is typical for IL-1 ligands (7). In fact, both IL-1␤ and IL-18 are produced as inactive precursors, which require cleavage by caspase-1 for secretion and activity (9, 10). Furthermore, IL-18 acts via the receptors IL-1R related protein 1 (IL-1Rrp1) 3 (IL-1R5) and IL-1R accessory protein-like (IL-1RAcPL) (IL-1R7) (11-13). Both receptors belong to the IL-1R family (see legend to Table I for a list of IL-1R family members and the numbering system used in this paper). IL-18 also activates signaling components which are involved in classical IL-1 signaling (7, 24) .
IL-18 is critical in eliciting IFN
I nterleukin-18 is a pleiotropic cytokine initially discovered as an IFN-␥ inducing factor derived from liver cells (1, 2) . Other biological activities of IL-18 include its ability to induce the production of inflammatory mediators, to enhance the cytotoxic activity of NK cells and T cells, and to augment the differentiation and activation of Th1 cells (1, (3) (4) (5) (6) (7) . IL-12 and IL-18 single and double-knockout mice suggest that IL-18 is functionally closely related to IL-12 and plays a fundamental role in Th1 cell responses (8) . However, IL-18 is predicted to fold as a ␤-rich trefoil, which is typical for IL-1 ligands (7). In fact, both IL-1␤ and IL-18 are produced as inactive precursors, which require cleavage by caspase-1 for secretion and activity (9, 10) . Furthermore, IL-18 acts via the receptors IL-1R related protein 1 (IL-1Rrp1) 3 (IL-1R5) and IL-1R accessory protein-like (IL-1RAcPL) (IL-1R7) (11) (12) (13) . Both receptors belong to the IL-1R family (see legend to Table I for a list of IL-1R family members and the numbering system used in this paper). IL-18 also activates signaling components which are involved in classical IL-1 signaling (7, 24) .
The potent responses of IL-1␣/␤ as well as IL-18 are tightly controlled by separate natural regulatory systems. IL-1 receptor antagonist (IL-1ra) and IL-1R2, for instance, antagonize the response to IL-1␣/␤ at the ligand and (co)receptor levels (25) (26) (27) (28) , whereas the soluble IL-18 binding protein antagonizes IL-18 by preventing its access to its receptor (29, 30) . Numerous studies have shown that perturbation of such control mechanisms contributes to the pathogenesis of inflammatory and infectious diseases and various cancers (31, 32) , and, in the case of IL-18, particularly to endotoxin-induced liver injury and Th1-mediated autoimmune disorders (1, (33) (34) (35) (36) (37) . Interference with the IL-18 ligand-receptor interaction has proven to be an effective strategy for the development of IL-18 antagonists. For instance, anti-IL-18 Abs protect mice primed with Propionibacterium acnes and challenged with LPS from liver damage and inhibit progression of experimental acute encephalomyelitis in rats (1, 34) . The soluble IL-18 binding protein inhibits bacterial-induced IFN-␥ production (29) . Moreover, anti-IL-1R5 Ab reduces Th1 responses to LPS (38) . Even though IL-1R5 is a functional component of the IL-18R, its binding affinity for IL-18 is relatively low (11) . However, both high and low affinity binding sites for IL-18 were observed on IL-12-pretreated T and B lymphocytes (39) . IL-1R7, a candidate receptor to explain this discrepancy, has not been analyzed in great depth with respect to its role in ligand-receptor interaction or its expression on inflammatory effector cells and not at all with respect to its potential as a target to inhibit inflammatory pathologies.
In this report, we show that in the context of the IL-1 system IL-1R7 is highly specific for the IL-18 response. IL-1R7 is furthermore required for high affinity binding of IL-18, and is coexpressed with IL-1R5 on Th1 but not Th2 cells. We prepared an anti-IL-1R7 mAb 28E3, wich effectively inhibited IL-18 responses in vitro. This result independently confirms the critical role of IL-1R7 in IL-18 action.
IL-18 and IL-1ra were produced at DNAX. Anti-mouse IL-18 mAb C18.6 and the corresponding isotype control Ab were obtained from BD PharMingen. The Cop5 cell line was maintained in DMEM supplemented with 5% FBS and 10 g/ml ciprofloxacin (Miles, Kankakee, IL). The Jurkat E6.1 cell line was maintained in RPMI 1640 medium supplemented with 10% FBS, and 100 U/ml penicillin and 100 g/ml streptomycin (Life Technologies, Paisley, U.K.). The HDK-1 Th1 clone was cultured as described previously (40) .
Brief description on cloning of human and mouse IL-1R7
Searching the public murine expressed sequence tag (EST) database with the intracellular portion of murine IL-1R3 revealed EST 27d04.r1 (GenBank accession no. AA203986), which was ordered from the IMAGE consortium. A full-length mouse IL-1R7 containing clone was pulled out a spleen library using primers (5Ј-GCAGCAGTGAATCTTGCCTTGGTT and 3Ј-GCAGAGGTCTGGAGTATTGC) covering the latter half of the Toll Homology Domain (i.e., blocks 5-10) (23) (Genome Systems, St. Louis, MO). The search for the human homologue of murine R7 started off by the finding of two human ESTs (HGBFD13R, HCFCJ10R) in the Human Genome Sciences database (HGS, Rockville, MD) using the mouse EST as a query. The insert of clone HGBFD13R was 32 P-labeled and used to probe a cDNA library of activated HY06 cells (a Th1 clone). Analysis of positive clones extended the sequence up to the second Ig domain, and again the full-length sequence was obtained by screening a spleen library with primers (5Ј-TGATGTAGCCTGTTGTGTCAAGATG and 3Ј-GTACTGAGACTTCCCACTCTAGGTC) covering the latter half of the second and the complete third Ig domain (Genome Systems).
Expression vectors
For mammalian expression, vectors encoding full-length human and mouse IL-1R1, mouse IL-1R3, mouse IL-1R4, human and mouse IL-1R5, mouse IL-1R7, human IL-1R9, and human IL-1R10 were constructed by inserting PCR-generated cDNA fragments into pME18S (41) . Human IL-1R6 was a generous gift of Dr. R. A. Maki (Neurocrine Biosciences, San Diego, CA). Both human IL-1R6 and human IL-1R7 cDNA were subcloned directly into pME18S. The cDNAs encoding extracellular parts of mouse IL-1R5 and IL-1R7 were fused to a C-terminal Ig cDNA module and Etag, respectively, via PCR and inserted into pCDM8 (Invitrogen, Carlsbad, CA). The reporter gene plasmid pNF-B-Luc (Stratagene, La Jolla, CA) contains five NF-B sites and a basic promoter element to drive luciferase expression, and pRSV-␤Gal results in constitutive expression of ␤-galactosidase.
Protein expression and purification of mouse soluble IL-1R5 and IL-1R7
Cop5 cells ( 10 7 ) were transfected by electroporation (200 V, 960 mF) with 15 g of either mouse soluble IL-1R5 pCDM8.Ig or IL-1R7 pCDM8.Etag expression constructs (purified via Endo Free kit; Qiagen, Hilden, Germany). Cells (from five electroporations) were cultured in 1-liter culture medium using one 10-tray Cell Factory (Nunc, Kamstrup, Denmark). Seven to ten days posttransfection, supernatants were harvested by filtration and run over HiTrap columns (Amersham Pharmacia Biotech AB, Uppsala, Sweden) coupled with either protein A or anti-Etag mAb, respectively. Soluble R5 (sR5) and sR7 proteins were eluted with 0.1 M glycine, pH 3.0, neutralized by addition of Tris-HCl, pH 8.0, and dialyzed vs PBS. The protein content was quantified by ELISA according to standard procedures. Cells transfected with empty constructs or with constructs containing an irrelevant insert provided mock controls. Endotoxin levels were determined using the Limulus amebocyte lysate assay (BioWhittaker, Walkersville, MD) and were Ͻ2.5 endotoxin units per 100 g of protein. Protein samples were stored at 4°C.
Preparation of rat anti-mouse IL-1R7 mAb
Rat anti-mouse IL-1R7 mAbs were produced from splenocytes of an 8-wkold female Lewis rat (Harlan Sprague-Dawley, Indianapolis, IN) immunized with mouse sIL-1R7:Etag fusion protein. The rat was primed i.p. with 25 g of fusion protein in CFA and boosted three times i.p. with 10 g (day 25), 5 g (day 40), and 10 g (day 54) in IFA, respectively. The final boosts were done both i.v. and i.p. at day 83 with 10 g of fusion protein in saline solution and IFA, respectively. Splenocytes were fused at day 87 with the mouse myeloma P3X63-AG8.653 using PEG 1500 (Roche Diagnostics, Mannheim, Germany). Hybridoma supernatants were screened by indirect ELISA, Western blot, and FACS analysis. Selected positive hybridoma lines were subcloned and grown in serum-free medium supplemented with SITE (Sigma, St. Louis, MO). Abs were purified via HiTrap SP and Q columns (Amersham Pharmacia Biotech), and screened for their ability to inhibit IL-18-induced biological responses such as activation of NF-B and production of IFN-␥.
Radiolabeling of IL-18
Human IL-18 was radioiodinated using the Bolton-Hunter Reagent, and subsequently purified to homogeneity via ion-exchange chromatography (Mr. G. Brown, Amersham Pharmacia Biotech). Specific radioactivity of the preparations was about 0.1 Ci/ng protein. The labeled IL-18 preparations were tested for their capacity to induce production of IFN-␥ by the human NK cell line NKL.23. 
IL-18 receptor binding assay
The following IL-1R and IL-1R-like molecules (except IL-1R8) were used for transfections: IL-1RI (termed IL-1R1) (14) ; IL-1RII (IL-1R2) (15); IL-1R accessory protein (IL-1RAcP) (IL-1R3) (16); T1/ST2 (IL-1R4) (17, 18) ; IL-1R-related protein 1 (IL-1Rrp1) (IL-1R5) (19) and 2 (IL-1R6) (20) ; IL-1RAcPL (IL-1R7) (12) ; single Ig domain IL-1R-related protein (SIGIRR) (IL-1R8) (21); IL-1R accessory protein-like (IL-1RAPL) (IL-1R9) (22) ; and IL-1R10 (T. R. Sana, R. Debets, J. C. Timans, J. F. Bazan, and R. A. Kastelein. Submitted for publication). The receptor numbering is in keeping with our previously proposed numbering system (23) . IL-1R-induced NF-B activities in Jurkat cells were assayed as described in the legend to Fig. 1A . A plus sign was assigned when IL-1 stimulation of Jurkat IL-1R cotransfectants resulted in luciferase values, normalized for ␤-galactosidase activities, which were at least 3 times higher than background values (i.e., medium only). Data are from one of two to three independent experiments with similar results. layered over 150 l of phthalate oil (dibutylphthalate:bis(2-ethylhexyl)phthalate, 3:2; Fluka, Milwaukee, WI) and centrifuged at 5000 ϫ g for 10 min at 4°C. Cell-bound and cell-free radioactivity were measured in a gamma counter. Receptor binding data were analyzed by the Scatchard Coordinate System.
Quantitation of mRNA expression
A panel of DNAX mouse cDNA libraries, derived from various tissues and cellular sources (42, 43) , was used for Taqman-PCR analyses. The Th1 and Th2 cells were prepared as described previously (44) . RNA was isolated by the guanidium/phenol method (45) . Reverse transcriptase reactions were performed with SuperScriptII (Life Technologies) according to the supplier's instructions, except that random hexamers (Promega, Madison, WI), at a final concentration of 1.25 M, were added to the reaction. cDNAs (50 ng per reaction) were analyzed for the expression of IL-1R5 and IL-1R7 genes by the fluorogenic 5Ј-nuclease PCR assay (46) , using an ABI Prism 7700 Sequence Detection System (Perkin-Elmer Applied Biosystems, Foster City, CA). Reactions were incubated for 2 min at 50°C, denatured for 10 min at 95°C and subjected to 40 two-step amplification cycles with annealing/extension at 60°C for 1 min followed by denaturation at 95°C for 15 s. The amplicons for IL-1R5 (nt 272-344, with numbers starting at the initiator codon) and IL-1R7 (nt 11-82) were analyzed with FAM-labeled probes. Total cDNA quantities were prenormalized to a household gene (GAPDH), and values were expressed as femtograms per 50 ng total cDNA.
Reporter assay
For reporter gene assays, Jurkat E6.1 cells (4 ϫ 10 6 ) were transiently transfected by electroporation (300 V, 960 mF) with 2 g of pNF-B-Luc reporter gene plasmid, 0.5 g of pRSV-␤Gal and 4 g of each IL-1R-encoding cDNA (except when indicated otherwise). Twenty hours posttransfection, cells were stimulated with 20 ng/ml of human IL-1␣, IL-1␤, IL-18, or IL-1ra for 6 h. Cells were lysed using Reporter Lysis Buffer (Promega), and luciferase and ␤-galactosidase activities were assessed using Luciferase Assay Reagent (Promega) and Galacto-Light Kit (Tropix, Bedford, MA), respectively. Luciferase activities (in relative light units (RLU)) were normalized on the basis of ␤-galactosidase activities. Inhibition studies of mouse IL-18-mediated activation of NF-B were performed under suboptimal conditions. Cells were transfected with 50 ng IL-1R5/7 cDNAs, and stimulated with 1 ng/ml IL-18 with or without anti-IL-1R7 hybridoma supernatants and sIL-1R5 and/or IL-1R7 protein preparations at varying concentrations. Hybridoma supernatants were concentrated using 50 kDa M r cutoff filters (Millipore, Bedford, MA).
IL-18 bioassay
The Th1 clone HDK1 (40) was used to assay IL-18-induced production of IFN-␥ at least 10 days after Ag stimulation, and after culture in medium with IL-2 alone (7). In short, cells were seeded in 96-well plates at 5 ϫ 10 4 cells/well in the presence of suboptimal amounts of IL-18 (2 ng/ml) and IL-12 (0.2 ng/ml), with or without purified mAbs at the indicated concentrations. Supernatants were collected at 48 h and assayed for IFN-␥ using a two-site sandwich ELISA (47, 48) with a sensitivity of 125 pg/ml.
Results

IL-1R5 and IL-1R7 are highly specific for IL-18-induced activation of NF-B
To study the specificity of the IL-18R components for the IL-18 response within the IL-1 system of receptors and ligands, we matched all possible pairs of IL-1Rs and IL-1R-like molecules with known IL-1 ligands, using luciferase as a reporter for receptor-mediated activation of NF-B (see Table I ). These experiments revealed that the IL-1R pair IL-1R5/7 is solely responsive to IL-18 (see Fig. 1A ). In addition, the response to IL-18 is only observed when IL-1R5 is paired with IL-1R7, and not with any other combination of IL-1Rs containing either IL-1R5 or IL-1R7 (see Fig.  1B ). The total set of IL-1(R) pairing data (Table I) shows that the IL-1R5/R7 pair is unique to the IL-18 response, whereas the IL-1R1/R3 pair is unique to the IL-1␣␤ response. Mock or single receptor transfectants never showed a ligand-induced response (data not shown).
IL-1R5 and IL-1R7 cotransfectants provide low and high affinity binding to IL-18
To determine whether IL-1R7 contributes to the binding affinity of IL-18, binding studies on IL-1R5 and IL-1R7 double-transfectants were performed. We radiolabeled and purified human IL-18 via different methods and checked the integrity of the labeled molecule with an NK cell line-based bioassay. Studies showed that labeling on either tyrosine or lysine residues is succesful, but that purification via HPLC is detrimental for the biological activity of the cytokine, whereas other purification schemes did not affect the integrity of the cytokine (data not shown). We found labeling with the Bolton Hunter Reagent followed by purification using ion-exchange chromatography to work best. At least 40% of IL-1R5/7 transfected cells had to express protein, based on analysis of parallel transfectants with green fluorescent protein, for binding to be successful. Expression of both human IL-1R5 and IL-1R7 by 293-T cells resulted in a dose-dependent specific binding of radioiodinated IL-18 ( Fig. 2A) . Scatchard analyses, as presented in Fig.  2B , revealed that expression of both receptors resulted in lowaffinity binding (ϳ4300 binding sites per cell with K d : 11 nM) and high-affinity binding (ϳ540 binding sites per cell with K d : 400 pM).
Inhibition of IL-18-induced activation of NF-B by anti-IL-1R7 mAb TC30-28E3, but not by soluble receptors
We prepared a panel of rat anti-mouse IL-1R7 hybridomas. Hybridoma supernatants were tested for their ability to inhibit IL-18-induced activation of NF-B in IL-1R5/7-transfected Jurkat cells. Supernatants of 3 of 20 clones showed a dose-dependent inhibition of NF-B activation, with the TC30-28E3 clone giving the strongest and most consistent inhibition (illustrated in Fig. 3A) . Mouse sIL-1R5 and sIL-1R7 proteins did not affect the IL-18-induced activation of NF-B (Fig. 3B) .
Th1 but not Th2 cells uniquely express both IL-1R5 and IL-1R7 mRNA
To extend our analyses of mAb TC30-28E3 to responses mediated via physiologically expressed IL-18R components, we determined the RNA expression profile of IL-1R5 and IL-1R7 in a broad panel of cDNA libraries derived from various tissues and cell types. Quantitative PCR showed that these receptors were in fact coexpressed to significant levels almost exclusively on Th1 cells (Fig.  4) . Th2 cells only expressed IL-1R7 mRNA to some extent, but not IL-1R5 mRNA.
Anti-IL-1R7 mAb TC30-28E3 is a potent antagonist of the IL-18-induced production of IFN-␥ by Th1 cells
The Th1 clone HDK1, which coexpresses both IL-18 receptor components, was used to monitor the potential of anti-IL-1R7 mAbs to inhibit IL-18-induced production of IFN-␥. Monoclonal Ab TC30-28E3 again proved to be most effective in inhibiting this response, in agreement with results obtained in the NF-B activation assay. In fact, in the total set of Abs generated, there was a clear correlation between the effects on activation of NF-B and the effects on IFN-␥ production by either LPS-treated splenocytes or the Th1 clone HDK-1 (data not shown). Monoclonal Ab TC30-28E3 was purified and compared with anti-IL-18 ligand mAbs for their potency to inhibit IL-18-induced production of IFN-␥ by HDK1 cells (Fig. 5) . Anti-IL-18 mAb C18.6 showed similar levels of inhibition only at concentrations being at least 10-fold higher relative to mAb TC30-28E3 (Fig. 5) . For a second anti-IL-18 mAb C18.7, the observed potency to antagonize the IFN-␥ production by Th1 cells was even less than that of C18.6 (data not shown). Isotype control Abs did not affect the IL-18-induced production of IFN-␥ by HDK-1 cells.
Discussion
Our studies focused on the specificity and binding characteristics of the IL-18R components, and the subsequent development and functional screening of anti-IL-1R7 mAb TC30-28E3. In this study, we report for the first time that: 1) both IL-18 receptor components (i.e., IL-1Rrp1 (IL-1R5) and IL-1RAcPL (IL-1R7)) are not only involved in the IL-18 response, but are in fact highly specific and unique for such a response; 2) IL-1R7 contributes to high affinity binding of IL-18; 3) Th1 but not Th2 cells coexpress both IL-18R components; and 4) the anti-IL-1R7 mAb TC30-28E3 potently inhibits IL-18-induced responses.
The IL-18R components both harbor extracellular Ig-folds and an intracellular domain homologous to the cytosolic part of the Drosophila Toll protein, characteristic of IL-1R and IL-1R-like molecules (see the legend to Table I for a list of IL-1R family members). The receptors of the IL-1 system typically comprise two separate receptor subunits, a ligand-binding receptor subunit and a signaling receptor subunit to establish a ligand-induced biological response. To study the specifity of IL-18R usage within the IL-1 receptor-ligand family, we functionally matched all possible pairs of IL-1Rs and IL-1R-like proteins with all known IL-1 ligands and IL-18. We found the IL-18-induced activation of NF-B highly specific at the receptor level (Fig.  1) . In fact, the total set of IL-1(R) pairing data (Table I) shows that the absence of redundancy of receptor usage applies to both known IL-1-type responses (i.e., IL-18 response via IL-1R5/7 and IL-1␣␤ response via IL-1R1/3). These observations suggest that the IL-1 family of ligands differ from the hemopoietic cytokines which signal through a common signaling receptor (i.e., common ␤, common ␥, and the gp130 chain).
The IL-1␣/␤ receptor expresses both low and high affinity binding sites for IL-1␣/␤ (49). The majority of cellular binding sites expresses low-affinity binding for IL-1␣␤, which are thought to depend on the expression of IL-1R1 alone (K d about 1 nM). High- (39) . IL-1R7 seems not be able to bind IL-18 (12), but its possible role in increasing the affinity of IL-1R5 for IL-18 is unclear. To address this issue, we performed binding studies with cells expressing both IL-1R5 and IL-1R7. Coexpression of both IL-1R5 and IL-1R7 indeed resulted in low and high affinity binding of IL-18 ( Fig. 2) , with binding properties similar to those found for IL-12 pretreated T cells. These data suggest that IL-1R5 and IL-1R7 form a complex that functions as a high affinity binding site for IL-18.
The observations that IL-1R7 is highly specific for the IL-18 response and is required for high affinity binding to IL-18, suggested the utility of anti-IL-1R7 mAbs to block IL-18-mediated responses. We prepared a panel of rat anti-mouse IL-1R7 mAbs, of which mAb TC30-28E3 effectively inhibited the IL-18-induced activation of NF-B (Fig. 3) . Induction of direct cell death by the IgG2a isotype mAb TC30-28E3 via complement-mediated cytotoxicity was ruled out (tested by trypan blue dye exclusion, not shown). Soluble R5 and R7 proteins did not affect the IL-18-induced activation of NF-B. This is somewhat unexpected because sR1 and sR2 proteins were reported to inhibit IL-1-mediated responses in vitro and in vivo (50, 51) . Moreover, sR5 but not sR7 protein has been found to bind IL-18 in solution (12) . However, the binding affinity of IL-1R5 for IL-18 is at least 20-fold lower than the binding affinity of IL-1R1 for IL-1 (11, 49) , and the binding affinity of sR5 for IL-18 may even be lower than that of membrane-bound R5. BIAcore biosensor studies confirmed that sR5 but not R7 bound IL-18 only to a weak extent (data not shown). Poor binding properties of sR5 and R7 probably account for their inability to block IL-18-mediated activation of NF-B.
Others have reported that IL-1R5 is expressed exclusively on Th1 cells relative to Th2 cells (38, 39) . We have extended this finding by showing that Th1 cells, among a broad panel of various tissues and cell types, are unique in coexpressing significant levels of both IL-1R5 and IL-1R7 mRNA (Fig. 4) . Th1 but not Th2 cells also express IL-12R␤2 (52), which is selectively lost in early Th2 cells (53) . Whether IL-18R subunits are also selectively lost in early Th2 cells needs yet to be determined. We extended our analyses of mAb TC30-28E3 to responses mediated via endogenously expressed IL-18 receptors by Th1 cells. Monoclonal Ab TC30-28E3 potently inhibited LPS-induced production of IFN-␥ by spleen cells (not shown) as well as IL-18-induced production of IFN-␥ by the Th1 clone HDK1, and proved to be a more potent antagonist than anti-IL-18 mAb (Fig. 5) . The TC30-28E3 mAb and the anti-IL-18 mAb used in this study may bind to their respective target Ags with different affinities or IL-1R7 may in fact represent a more efficient target than IL-18 to block IL-18-mediated responses. The synergy between IL-18 and IL-12 to induce production of IFN-␥, which is probably the result from reciprocal upregulation of their receptors (38, 54) and the use of distinct signaling pathways to enhance IFN-␥ gene transcription (55), depends only partly on the activation of NF-B (56). mAb TC30-28E3 therefore most likely blocks the ability of IL-18 to activate additional transcription factors such as AP-1 and possibly others. Our in vitro data are in line with preliminary in vivo data, which show that mAb TC30-28E3, especially in combination with anti-IL-12 mAb, abrogates the clinical progression of Th1-mediated diseases, such as Listeria infection (A.O., manuscript in preparation) or Legionella infection. 4 Taken together, our study provides in vitro evidence that IL-1R7 confers responsiveness to IL-18 in a highly specific and unique manner, is required for high affinity binding of IL-18, and is coexpressed with IL-1R5 on Th1 cells only. Moreover, the anti-IL-1R7 mAb TC30-28E3 has properties highly suited to testing the therapeutic utility of anti-IL-1R7 Abs in inhibiting Th1-mediated pathologies.
FIGURE 5. Anti-IL-1R7 mAb TC30-28E3 is a potent antagonist of the IL-18-induced production of IFN-␥ by Th1 cells. IL-18-induced production of IFN-␥ was assayed using clone HDK1. Cells were cultured in the presence of IL-18 (2 ng/ml) and IL-12 (0.2 ng/ml), with or without purified anti-IL-1R7 mAb TC30-28E3, anti-IL-18 mAb C18.6 or their corresponding isotype control Abs at the indicated concentrations. Supernatants were collected at 48 h and assayed using an IFN-␥ ELISA. The concentration of IFN-␥ without mAb was 0.317 Ϯ 0.115 ng/ml. The isotype control Abs had a negligible effect on the production of IFN-␥, which is shown for one representative Ab. Data are presented as mean Ϯ SD of triplicates of one experiment of two with similar results.
